• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk
Partnership combines Roche ’s proven track record of successfully developing and launching innovative medicines worldwide withAlnylam ’s leadership in RNAi therapeuticsZilebesiran, a Phase 2 RNAi therapeutic, has best-in-disease potential for patients with hypertension at high risk of cardiovascular morbidity and mortality, by robustly and durably lowering blood pressureHypertension, the leading cause of cardiovascular disease, affects more than 1.2 billion adults worldwide. While several therapies exist, a significant unmet need, especially for high risk patients, remains.1Basel, 24 July 2023 - Roche (SIX: RO, ROG; OT...
Source: Roche Investor Update - July 24, 2023 Category: Pharmaceuticals Source Type: news

Pregnancy-Associated Takotsubo Cardiomyopathy Hospitalizations in the United States
Am J Physiol Heart Circ Physiol. 2023 Jul 7. doi: 10.1152/ajpheart.00262.2023. Online ahead of print.ABSTRACTTakotsubo cardiomyopathy (TCM) is most common in postmenopausal women aged ≥ 50 years but also affects pregnant individuals. However, there are no national estimates on the prevalence, timing of occurrence, correlates, and outcomes of Pregnancy-associated TCM. Using the Nationwide Inpatient Sample (NIS: 2016-2020), we describe rates of pregnancy-associated TCM hospitalizations among 13 - 49 years old pregnant individuals in the United States by selected demographic, behavioral, hospital, and clinical characteristi...
Source: American Journal of Physiology. Heart and Circulatory Physiology - July 7, 2023 Category: Physiology Authors: Mulubrhan F Mogos Soojung Ahn James M Muchira Sarah Osmundson Mariann R Piano Source Type: research

In-hospital stroke and mortality trends after left ventricular assist device implantation in the United States from 2017 to 2019
CONCLUSIONS: Our study found a significant downtrend in the in-hospital mortality rates among patients with LVAD without substantial changes in stroke rate trends over the study timeframe. As stroke rates remained steady, we hypothesize that improved management along with better control of blood pressure, could have played an important role in survival benefit over the study time frame.PMID:37387231 | DOI:10.1177/03913988231183723
Source: The International Journal of Artificial Organs - June 30, 2023 Category: Transplant Surgery Authors: Jose Lopez Justin Mark Waseem Wahood Nader Lamaa Mauricio Danckers Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15